The Pleiotropic Effect of Complement C5a-C5aR1 Pathway in Diseases: From Immune Regulation to Targeted Therapy
Open Access
- 3 December 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (23) , 11693
Abstract
The complement system plays a pivotal role in the body’s immune defense mechanism. Its key effector molecule C5a and its primary receptor C5aR1 exhibit complex “double-edged sword” effects in various disease processes, including infectious diseases, inflammatory conditions, tumors, and metabolic disorders. Under normal physiological conditions, moderate levels of C5a bind to the C5aR1 receptor, recruiting immune cells to the site of infection to participate in immune defense and enhancing the body’s ability to clear pathogens. However, in various disease states, the C5a-C5aR1 pathway primarily shapes the disease microenvironment through regulating cellular pro-inflammatory and immune functions, angiogenesis processes, and tissue repair processes. It also promotes tumor immune escape through a novel mechanism through modulating the polarization of myeloid-derived suppressor cells (MDSCs) and regulating T cell function. The C5a-mediated “inflammation–fibrosis–metabolic reprogramming” vicious cycle has become a key molecular basis driving disease progression, maintaining pathological states, and promoting abnormal tissue damage repair in chronic inflammatory diseases. Through elucidating the structural biology of C5aR1 and designing allosteric modulators, nanobodies, and bifunctional molecules as new targeted intervention strategies, we aim to accelerate research progress in related medical fields. This article reviewed the molecular mechanisms of the complement system in tumor immune escape, chronic inflammation, fibrosis, and cardiovascular diseases, and explored the translational potential of targeted interventions. These discussions provide a solid theoretical foundation and new research perspectives for the medical field, aiding in the advancement of further discoveries.Keywords
Funding Information
- The earmarked fund for CARS (CARS-45)
This publication has 83 references indexed in Scilit:
- Understanding the role of C5a/C5aR1-mediated complement activation pathway in tumor progression and therapy resistanceScience China Life Sciences, 2025
- The complement system as a target in cancer immunotherapyEuropean Journal of Immunology, 2024
- Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptorsCell, 2023
- Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarizationJournal of Gastroenterology, 2023
- Intracellular complement C5a/C5aR1 stabilizes β-catenin to promote colorectal tumorigenesisCell Reports, 2022
- Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and functionBiochemical Pharmacology, 2020
- Complement: Bridging the innate and adaptive immune systems in sterile inflammationJournal of Leukocyte Biology, 2020
- Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosisBreast Cancer, 2015
- Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two‐year prospective study (the DAMAGE study cohort)Arthritis & Rheumatism, 2006
- Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide‐stimulated monocytes and macrophagesEuropean Journal of Immunology, 1990